stockrow
Monday 9 November 2026
Export KROS’s income statement to Excel — free account
Keros Therapeutics, Inc.
KROSKeros Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $244.1 million, up 6,775.0% from fiscal 2024.
- Revenue
- +120.2%
- EPS
- +494.4%
- Free cash flow
- +6.87%
Quarter to September 2026, against a year earlier
9.36
0.09
−0.95%
Follow KROS
Alert me
Keros Therapeutics, Inc. (KROS) P/E ratio
Keros Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 45.9× (September 2025) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 10.9× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 10.9× | 9.32% |
| Sep 2025 | 10.0× | (73.75%) |
| 14 more quarters | Free account |
Against its own ten years
Low 0.0×
High 45.9×
Ten-year median
0.0×
Current reading's percentile
89
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| TRDA Entrada Therapeutics, Inc. compare | n/m |
| RNA Atrium Therapeutics, Inc. compare | n/m |
| KROS Keros Therapeutics, Inc. | n/m |
| IFRX InflaRx N.V. compare | n/m |
| PYXS Pyxis Oncology, Inc. compare | n/m |
| BCYC Bicycle Therapeutics PLC Sponsored ADR compare | n/m |
| ACOG Alpha Cognition Inc. compare | n/m |
| PRQR ProQR Therapeutics N.V. compare | n/m |
| CGEN Compugen Ltd. compare | 5.2× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)